Clinical · Molecular biology
Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection
This retrospective study investigated the clinical, surgical, and molecular characteristics and outcomes of 52 adult patients with H3 K27-altered diffuse midline glioma (DMG) treated with surgical resection. The median overall survival was 17.8 months. Genomic profiling revealed a distinct molecular landscape dominated by H3F3A mutations, frequently co-occurring with TP53 mutations, and a significant enrichment of mutations within the RTK/RAS/PI3K signaling pathway, involving NF1, FGFR1, and PIK3CA. Postoperative adjuvant radiotherapy combined with temozolomide emerged as the sole independent protective factor for overall survival. While maximal safe resection is considered essential, molecular targeted therapies did not achieve independent statistical significance.